V2ACT / V2ACT Therap - LARVOL DELTA

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC (GlobeNewswire) - "Genelux Corporation...and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted a patent claiming methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy. The patent has been exclusively licensed to V2ACT Therapeutics, LLC, a joint venture between Genelux and TVAX that was established for the purpose of developing and testing V2ACT Immunotherapy. The patent expiry, prior to any patent term extension, will be in 2036 and will add substantial intellectual property protection for V2ACT Immunotherapy."

Patent • Oncology • Solid Tumor

V2ACT Therapeutics on Track to Launch Phase I/IIa Pancreatic Cancer Trial, Following FDA Nod (BioSpace) - "'The Phase 2 data in PRROC patients demonstrated remarkable overall survival in combination with a platinum-based regimen, especially in the difficult-to-treat platinum-refractory disease population, considering these patients were heavily pretreated and largely at pre-hospice stage,' said Robert Holloway, MD, the principal investigator of the Phase II trial and Chair..."

IND • Media quote

V2ACT Therapeutics, LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer (PRNewswire) - "V2ACT Therapeutics™, LLC today announced that the Company has obtained permission from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application and may proceed with the clinical investigation of V2ACT in a Phase 1/2a trial for the treatment of newly diagnosed surgically-resectable pancreatic cancer patients."

IND • Gastrointestinal Cancer • Oncology • Pancreatic Cancer